Precision Psychiatric Hormone Management

Hormonal dysregulation is a psychiatric diagnosis

Testosterone deficiency, subclinical hypothyroidism, progesterone loss, and DHEA depletion are not separate from psychiatric illness — they are drivers of it. At Welmivia, hormonal optimization is a clinical intervention, not a performance enhancement.

Schedule a Fit Call

Welmivia Hormonal Scope

  • Testosterone

    Men & women — mood, cognition, motivation, libido, treatment resistance

  • Thyroid (T3/T4)

    T3 monotherapy and combination for TRD augmentation; subclinical hypothyroidism

  • Progesterone

    PMDD, perimenopausal mood disorder, luteal phase dysregulation, postpartum

  • DHEA & Pregnenolone

    Neuroactive precursor optimization — stress resilience, memory, HPA regulation

  • Estradiol

    Perimenopausal and postmenopausal mood disorder; cognitive protection

  • Excluded

    Gender-affirming HRT — outside Welmivia scope

The Clinical Case

Hormones as psychiatric medicine

Hormonal dysregulation is a direct driver of mood dysregulation, cognitive dysfunction, treatment resistance, and psychiatric medication non-response.

Testosterone deficiency produces a syndrome clinically indistinguishable from Major Depressive Disorder — dysphoria, fatigue, anhedonia, cognitive slowing, reduced motivation — and is frequently misdiagnosed and treated with antidepressants that provide no benefit to the underlying deficiency.

Progesterone (as allopregnanolone) is a potent GABA-A positive allosteric modulator. Its dysregulation removes the brain's primary inhibitory protection against anxiety. Thyroid dysfunction mimics or exacerbates virtually every psychiatric condition.

The Optimal Range Principle

Standard laboratory reference ranges reflect population-based statistical norms — the range in which 95% of the general population falls. This is not the range associated with optimal psychiatric function. A patient with total testosterone of 280 ng/dL is within normal range. They are also likely symptomatic.

"Never document only 'within normal limits.' Always document the specific value, the patient's symptomatic status at that value, and the target range with clinical rationale."

Welmivia targets

Testosterone (men): 600–1,000 ng/dL  ·  Free T3 (TRD): mid-to-upper normal  ·  DHEA-S (chronic stress): upper quartile age-appropriate range

Qualifying Indications

Where hormones meet psychiatric diagnosis

Hormonal therapy at Welmivia is not initiated on patient request alone. Every intervention requires a documented psychiatric indication, a lab-confirmed abnormality or symptomatic deficiency, and a clinical narrative linking hormonal status to the psychiatric presentation.

DiagnosisHormonal RelevancePrimary Agents
F32–F33Major Depressive DisorderLow testosterone mimics MDD; hypothyroidism mimics MDD; T3 augmentation for TRD; estradiol depletion in perimenopause drives MDD onset; DHEA deficiency in chronic stressTestosterone, T3/T4, DHEA, Estradiol
F41.1Generalized Anxiety DisorderProgesterone deficiency reduces GABA-A inhibitory tone; DHEA/cortisol ratio dysregulation in chronic anxiety; allopregnanolone dynamics centralProgesterone, DHEA, Pregnenolone
F32.81PMDDPrimary hormonal-psychiatric disorder; driven by abnormal neurobiological sensitivity to progesterone/estradiol fluctuations; allopregnanolone dynamics centralProgesterone (primary), Estradiol
F43.10PTSDHPA axis dysregulation → cortisol → DHEA depletion; low DHEA:cortisol ratio is a PTSD biomarker; testosterone blunting from chronic stressDHEA, Testosterone, Pregnenolone
F31Bipolar DisorderLithium-induced hypothyroidism; T3 augmentation; valproate lowers testosterone in menT3/T4, Testosterone (monitored)
N95.1Perimenopausal Mood DisorderEstradiol decline is a direct trigger for new-onset MDD; testosterone decline contributes to motivation loss; progesterone loss removes GABAergic protectionEstradiol, Progesterone, Testosterone
F52Sexual DysfunctionTestosterone is the primary driver of desire in both sexes; low testosterone under-recognized in women with SSRI-induced sexual dysfunctionTestosterone, DHEA, Estradiol
F90ADHDTestosterone modulates dopaminergic tone and executive function; cyclical ADHD symptom variation in women tied to estradiolTestosterone, Thyroid, Estradiol

Agents & Mechanisms

The Welmivia hormonal formulary

Testosterone

Men & Women · Compounded Topical or SQ

Modulates dopaminergic and serotonergic tone, promotes neurogenesis, reduces neuroinflammation. In men: target 600–1,000 ng/dL. In women: precision low-dose compounded cream — female testosterone deficiency is dramatically under-recognized. Treat to symptom resolution.

Thyroid (T3/T4)

T3 Augmentation · Treatment-Resistant Depression

T3 (liothyronine) augmentation for treatment-resistant depression is an established evidence-based protocol. Free T3 — not TSH alone — required before initiation. Target mid-to-upper normal free T3 range. T3 enhances TCA and SSRI response. Monitor HR, BP, and QTc with TCAs.

Progesterone

PMDD · Perimenopause · Postpartum · Sleep

Bioidentical progesterone metabolizes to allopregnanolone — a potent GABA-A positive allosteric modulator with anxiolytic and sleep-promoting effects. Synthetic progestins do NOT convert to allopregnanolone and may worsen mood. Bioidentical only.

DHEA

Chronic Stress · PTSD · Adrenal Recovery

DHEA-S declines with age and chronic stress. Low DHEA:cortisol ratio is a documented PTSD biomarker. DHEA converts to both testosterone and estradiol — monitor downstream hormones after initiation. Individual conversion rates vary significantly.

Estradiol

Perimenopause · Postpartum · Cognitive Protection

Estradiol decline in perimenopause is a direct trigger for new-onset MDD. Transdermal route only — bypasses first-pass metabolism, eliminating VTE risk associated with oral estrogen. Note: carbamazepine significantly reduces estradiol levels and may require higher dosing.

Pregnenolone

Neurosteroid Precursor · Memory · Resilience

The master neurosteroid precursor — converts to DHEA, progesterone, and downstream hormones. Supports stress resilience, memory consolidation, and neurosteroid tone. Monitor full hormonal panel at 6–8 weeks. Individual conversion patterns vary widely.

Why "normal" isn't enough

The most common failure point in hormonal psychiatry is accepting lab results that are statistically normal but clinically insufficient. A patient with total testosterone of 280 ng/dL will have their MDD treated with another antidepressant. A patient with free T3 of 2.2 pg/mL will be told their thyroid is fine. At Welmivia, the clinical question is whether your hormonal status is contributing to your symptoms, and whether targeting an optimal range will change your psychiatric outcome.

Takeover Policy

Welmivia accepts hormone takeover cases

If you are currently receiving hormonal therapy from another provider and want to transfer care to Welmivia's psychiatric framework, takeover is available on a case-by-case basis.

Takeover requires a full evaluation visit, updated labs, and independent documentation of clinical rationale. Prior prescriber targets may not align with Welmivia's psychiatric framework.

Takeover protocol includes

  • Full prior treatment history: agent, dose, duration, response
  • Independent baseline labs — not from prior provider
  • Assessment of adverse effects (erythrocytosis, lipids, virilization)
  • Alignment of targets with Welmivia psychiatric framework
  • Documentation of psychiatric indication and clinical narrative

Getting Started

Every patient begins with a Precision Psychiatric Evaluation

1

Evaluation ($450)

Full psychiatric evaluation. Medication and hormonal history. Welmivia Blueprint including whether hormonal optimization is indicated.

2

Baseline Labs

Comprehensive hormonal panel — testosterone (total + free + SHBG), thyroid (TSH + Free T3/T4), DHEA-S, pregnenolone, progesterone, estradiol, CBC, CMP, lipids, PSA (men ≥40). Patient pays LabCorp/Quest directly.

3

Membership & Monitoring

Hormonal optimization managed within Core or Signature membership follow-up visits. Compounded medications prescribed through Empower or Preston's Pharmacy. Superbills available on request.

Common Questions

Common patient questions

My doctor told me my hormones are normal. Why would I need hormonal treatment at Welmivia?
Standard reference ranges are population norms — statistically normal for 95% of the general population. A testosterone level of 280 ng/dL is technically within normal range. A patient at that level is also likely experiencing fatigue, dysphoria, anhedonia, and cognitive slowing that may look exactly like treatment-resistant MDD. At Welmivia, the question is whether your hormonal status is contributing to your symptoms, and whether targeting an optimal range will change your outcome.
Does Welmivia prescribe testosterone to women?
Yes. Female testosterone deficiency is dramatically under-recognized and under-treated. Testosterone is essential for libido, energy, mood, and cognitive function in women. Welmivia uses precision low-dose compounded creams and treats to symptom resolution rather than a reference range number. Clinical indications include MDD, sexual dysfunction, ADHD, perimenopausal mood disorder, and SSRI-induced loss of motivation or desire.
What is T3 augmentation for treatment-resistant depression?
T3 (liothyronine) augmentation is an established evidence-based protocol for patients with MDD who have had inadequate response to antidepressants. Welmivia uses free T3 measurements (not TSH alone) before initiation, targets the mid-to-upper normal free T3 range, and monitors heart rate, blood pressure, and QTc with concurrent TCA use.
I'm already on hormone therapy from another provider. Can I transfer care?
Yes, on a case-by-case basis. Welmivia accepts hormonal therapy takeover cases. This requires a full Precision Psychiatric Evaluation, updated labs drawn independently, and documentation of a psychiatric clinical rationale. Dr. Diaz does not continue a prior prescriber's protocol without her own independent assessment.

Common Questions

Common patient questions

My doctor told me my hormones are normal. Why would I need hormonal treatment at Welmivia?
Standard reference ranges are population norms — statistically normal for 95% of the general population. A testosterone level of 280 ng/dL is technically within normal range. A patient at that level is also likely experiencing fatigue, dysphoria, anhedonia, and cognitive slowing that may look exactly like treatment-resistant MDD. At Welmivia, the question is whether your hormonal status is contributing to your symptoms, and whether targeting an optimal range will change your outcome.
Does Welmivia prescribe testosterone to women?
Yes. Female testosterone deficiency is dramatically under-recognized and under-treated. Testosterone is essential for libido, energy, mood, and cognitive function in women. Welmivia uses precision low-dose compounded creams and treats to symptom resolution rather than a reference range number. Clinical indications include MDD, sexual dysfunction, ADHD, perimenopausal mood disorder, and SSRI-induced loss of motivation or desire.
What is T3 augmentation for treatment-resistant depression?
T3 (liothyronine) augmentation is an established evidence-based protocol for patients with MDD who have had inadequate response to antidepressants. Welmivia uses free T3 measurements (not TSH alone) before initiation, targets the mid-to-upper normal free T3 range, and monitors heart rate, blood pressure, and QTc with concurrent TCA use.
I'm already on hormone therapy from another provider. Can I transfer care?
Yes, on a case-by-case basis. Welmivia accepts hormonal therapy takeover cases. This requires a full Precision Psychiatric Evaluation, updated labs drawn independently, and documentation of a psychiatric clinical rationale. Dr. Diaz does not continue a prior prescriber's protocol without her own independent assessment.

Ready for a more integrated evaluation?

New patients begin with a Precision Psychiatric Evaluation to review symptoms, prior treatment, relevant labs, and whether hormone-related concerns should be incorporated into a broader cognitive and psychiatric optimization plan.

Ready to schedule?

Start with a Precision Psychiatric Evaluation

Interested in integrated GLP-1, hormone, peptide, hair, or sexual wellness support? New patients begin with a comprehensive Precision Psychiatric Evaluation to clarify goals, review history, and determine whether these services fit appropriately within your care plan.

Initial evaluation: $450
Virginia & Florida residents only
Direct-pay · Superbills on request

Ongoing monitored adjunctive therapies, including GLP-1 and peptide-based metabolic management, are addressed within the Welmivia care framework after evaluation when clinically appropriate.

Virginia & Florida Telehealth · Direct-Pay

Start with a free 10-minute fit call

Hormonal optimization at Welmivia begins with a $450 Precision Psychiatric Evaluation. Dr. Diaz reviews your full hormonal, psychiatric, and medication history and delivers a personalized Welmivia Blueprint.

Schedule Your Fit Call

Welmivia Medical, PLLC  ·  Dr. Sonia Mia Diaz, M.D.  ·  Virginia & Florida Telehealth  ·  Direct-Pay  ·  Superbills Available
This page is for informational purposes only. Hormonal therapy requires a clinical evaluation and active membership. Gender-affirming HRT is outside Welmivia's scope.